Table 1 Variable comparison between groups.
Variable | Group 1 (n = 77) | Group 2 (n = 20) | Group 3 (n = 63) | p α | p β (1 vs. 2) | p β (1 vs. 3) | p β (2 vs. 3) |
|---|---|---|---|---|---|---|---|
Female gender (%) | 51.9 | 70.0 | 53.9 | 0.34 | — | — | — |
Arterial hypertension (%) | 40.3 | 50.0 | 49.2 | 0.5 | — | — | — |
Proliferative retinopathy (%) | 36.3 | 30.0 | 19.0 | 0.08 | — | — | — |
Baseline visual impairment (%) | 51.9 | 55 | 28.6 | 0.01* | 1.0 | 0.005* | 0.03* |
Age (years, mean ± SD) | 57.5 ± 11.7 | 61.9 ± 8.3 | 53.8 ± 17.6 | 0.12 | — | — | — |
Diabetes duration (years, mean ± SD) | 14.5 ± 6.5 | 13.1 ± 7.4 | 15.4 ± 6.7 | 0.75 | — | — | — |
Fasting glycaemia (mg/dl, mean ± SD) | 158.1 ± 62.6 | 145.2 ± 57.4 | 184.3 ± 110.7 | 0.63 | — | — | — |
Visual acuity before treatment (logMAR, mean ± SD) | 0.40 ± 0.27 | 0.42 ± 0.28 | 0.27 ± 0.3 | 0.002* | 0.65 | 0.001* | 0.02* |
CPTγ before treatment (µm, mean ± SD) | 199.8 ± 30.4 | 166.8 ± 27.9 | 156.2 ± 20.3 | <0.001* | <0.001* | <0.001* | 0.16 |
CFT¶ before treatment (µm, mean ± SD) | 199.8 ± 30.4 | 166.8 ± 27.9 | 156.2 ± 20.3 | <0.001* | <0.001* | <0.001* | 0.16 |
Macular volume before treatment (mm3*, mean ± SD) | 8.08 ± 0.69 | 7.83 ± 0.52 | 7.4 ± 0.56 | <0.001* | 0.12 | <0.001* | 0.006* |
Visual acuity after treatment (logMAR, mean ± SD) | 0.40 ± 0.27 | 0.36 ± 0.29 | 0.24 ± 0.32 | <0.001* | 0.43 | <0.001* | 0.048* |
CPTγ after treatment (µm, mean ± SD) | 200.4 ± 36.4 | 168.9 ± 33.7 | 163.4 ± 26.1 | <0.001* | <0.001* | <0.001* | 0.70 |
CFTδ after treatment (µm, mean ± SD) | 229.1 ± 28.2 | 197.5 ± 20.7 | 194.1 ± 22.8 | <0.001* | <0.001* | <0.001* | 0.29 |
Macular volume after treatment (mm3, mean ± SD) | 7.83 ± 0.56 | 7.59 ± 0.51 | 7.27 ± 0.48 | <0.001* | 0.09 | <0.001* | 0.006* |
